Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer; he named the company after his two sons. The company initially sold its products in India, Russia, and Africa. The company went public in India in 1999, and used some of the proceeds to build its first research facility. Saldanha's son Glenn took over as CEO in 2001, having returned to India after working at PricewaterhouseCoopers. By 2008 Glenmark was the fifth-biggest pharmaceutical company in India.Finally A Good News In 2020 Fight Against Pandemic COVID19 Company Launched Under Brand Name FabiFlu. By 2011 the founder of the company was one of the richest men in India, and Glenmark had worldwide sales of $778 million, a 37% increase over the last year's sales; the growth was driven by Glenmark's entry into the US and European generics markets. In the mid-2010s the generics industry in general began transitioning to the end of an era of giant patent cliffs in the pharmaceutical industry; patented drugs with sales of around $28 billion were set to come off patent in 2018, but in 2019 only about $10 billion in revenue was set to open for competition, and less the next year. Companies in the industry responded with consolidation or trying to generate new, patented drugs. Glenn Saldanha took the company down the path of seeking innovation, which was controversial within the company and with shareholders. The company focused on new drugs and biosimilars in the fields of cancer, dermatology and respiratory diseases, which it sought to monetize by partnering with major pharmaceutical companies. In 2016 it had four such drugs in clinical trials. For the financial year 2016–2017 its sales were around 81 billion INR, making it the fourth-biggest Indian pharmaceutical company. In May 2019, Yasir Rawjee was elected as CEO of Glenmark Life Sciences.
Legacy products
Ryaltris
Glenmark Pharmaceuticals announced that it entered into an exclusive licensing agreement with Australia's Sequirus to commercialize its nasal spray Ryaltris™ which is a fixed-dose combination nasal spray of an antihistamine and a steroid, as a treatment for seasonal allergic rhinitis. Ryaltris, formerly GSP 301 Nasal Spray, has been conditionally accepted by the FDA as the brand name. ' Glenmark launches Covid-19 drug at Rs 103 per tablet. It is the first oral favipiravir-approved medication in India for the treatment of Covid-19. It further reduced the rate by 27% to Rs 75 per tablet. •It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, the drug firm said. •Availaible Through Retail & Hospital Channels •200 Mg Tablet, 34 Tablets in A Strip, ₹103/Tablet..Strip MRP ₹3500 •The company is producing the active pharmaceutical ingredients for the product at its Ankleshwar plant, while the formulation is being manufactured at its Baddi plant. •Finally A Good News In Fight Against COVID19. It's Launched Under Brand Name FabiFlu. 'Share market boom immediately after this, then again came down. It is expected that in next 2 months share price will cross double its current value.
•FabiFlu has shown clinical improvement of up to 88 per cent in mild to moderate COVID-19 cases, Company Said. Take • Take Proper Medical Guidance
